2024
Pre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients
Li J, Baker J, Aglago E, Zhao Z, Jiao L, Freisling H, Hughes D, Eriksen A, Tjønneland A, Severi G, Katzke V, Kaaks R, Schulze M, Masala G, Pala V, Pasanisi F, Tumino R, Padroni L, Vermeulen R, Gram I, Braaten T, Jakszyn P, Sánchez M, Gómez‐Gómez J, Moreno‐Iribas C, Amiano P, Papier K, Weiderpass E, Huybrechts I, Heath A, Schalkwijk C, Jenab M, Fedirko V. Pre‐diagnostic plasma advanced glycation end‐products and soluble receptor for advanced glycation end‐products and mortality in colorectal cancer patients. International Journal Of Cancer 2024, 155: 1982-1995. PMID: 39057841, DOI: 10.1002/ijc.35114.Peer-Reviewed Original ResearchConceptsAssociated with CRC-specificAdvanced glycation end productsPlasma advanced glycation end productsColorectal cancerCRC-specificOverall mortalityGlycation end productsSoluble receptorCancer patientsIntracellular signaling alterationsMultivariable-adjusted Cox proportional hazards regressionCancer and NutritionCox proportional hazards regressionEuropean Prospective InvestigationFollow-up periodColorectal cancer casesColorectal cancer patientsProportional hazards regressionUltra-performance liquid chromatography mass spectrometryColorectal cancer diagnosisEnzyme-linked immunosorbent assayColorectal cancer survivalProspective InvestigationChronic inflammationSRAGEImproved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly E, Shields A, Ogino S, Fuchs C, Meyerhardt J. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). Journal Of Clinical Oncology 2024, 42: 2853-2859. PMID: 38889377, PMCID: PMC11392453, DOI: 10.1200/jco.23.01680.Peer-Reviewed Original ResearchDisease-free survivalStage III colon cancerIII colon cancerRisk of recurrenceGain-of-function mutationsColon cancerWildtype patientsMutation statusImproved survivalUsage of COX-2 inhibitorsGain-of-functionStandard adjuvant chemotherapyCOX-2Primary end pointCyclooxygenase 2 inhibitionCOX-2 inhibitorsColorectal cancer diagnosisCOX-2 inhibitionWhole-exome sequencing dataNational Cancer InstitutePIK3CA statusOverall survivalAdjuvant chemotherapyStatistically significant improvementClinical trial updatePre‐diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study
Pham T, Nimptsch K, Aleksandrova K, Jenab M, Fedirko V, Wu K, Eriksen A, Tjønneland A, Severi G, Rothwell J, Kaaks R, Katzke V, Catalano A, Agnoli C, Masala G, De Magistris M, Tumino R, Vermeulen R, Aizpurua A, Trobajo‐Sanmartín C, Chirlaque M, Sánchez M, San Moon Lu S, Cross A, Christakoudi S, Weiderpass E, Pischon T. Pre‐diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study. International Journal Of Cancer 2024, 154: 1596-1606. PMID: 38200695, DOI: 10.1002/ijc.34830.Peer-Reviewed Original ResearchColorectal cancer diagnosisCRC-specific mortalityEuropean Prospective InvestigationAll-Cause MortalityCox proportional hazards modelsProportional hazards modelColorectal cancerCRC-specificAssociated with CRC-specific mortalityPre-diagnosticResistin concentrationsProspective InvestigationHazards modelHazard ratioIncident CRC casesFine-Gray proportional subdistribution hazards modelCause-specific Cox proportional hazards modelsSubgroup analysisBody mass indexNutrition CohortProportional subdistribution hazards modelMedian Follow-UpAssociated with increased mortalitySubdistribution hazard modelCRC cases
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic disease
2016
Su1816 Presence of Colonic Dysplasia prior to Colorectal Cancer Diagnosis is Associated with Early Stage Cancer among Patients with Inflammatory Bowel Disease: A National Cohort Study
Panara A, Zhang H, Waljee A, Gaidos J, Feagins L, Govani S, Thrift A, El-Serag H, Hou J. Su1816 Presence of Colonic Dysplasia prior to Colorectal Cancer Diagnosis is Associated with Early Stage Cancer among Patients with Inflammatory Bowel Disease: A National Cohort Study. Gastroenterology 2016, 150: s561. DOI: 10.1016/s0016-5085(16)31915-1.Peer-Reviewed Original Research
2015
Prediction of colorectal cancer diagnosis based on circulating plasma proteins
Surinova S, Choi M, Tao S, Schüffler PJ, Chang CY, Clough T, Vysloužil K, Khoylou M, Srovnal J, Liu Y, Matondo M, Hüttenhain R, Weisser H, Buhmann JM, Hajdúch M, Brenner H, Vitek O, Aebersold R. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Molecular Medicine 2015, 7: 1166-1178. PMID: 26253081, PMCID: PMC4568950, DOI: 10.15252/emmm.201404873.Peer-Reviewed Original ResearchConceptsColorectal cancer diagnosisBlood-based markersColorectal cancer detectionPatient's systemic circulationColorectal cancerSystemic circulationIndependent cohortCritical clinical needNon-invasive detectionDiagnostic valueClinical needTissue epitheliumCancer diagnosisPlasma samplesBiomarker signaturesPlasma proteinsBlood plasmaProtein biomarkersCancer detectionCandidate glycoproteinsClinical datasetsMass spectrometry-based approachCohortCancerDiagnosis
2013
Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009.
Yang D, Gross C, Yu J. Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009. Journal Of Clinical Oncology 2013, 31: 1522-1522. DOI: 10.1200/jco.2013.31.15_suppl.1522.Peer-Reviewed Original ResearchLate-stage colorectal cancerColorectal cancerCancer incidenceLate-stage colorectal cancer diagnosisEarly-stage colorectal cancerNon-screened populationColorectal cancer incidenceEnd Results (SEER) databaseColorectal cancer incidence dataAdults 50 yearsColorectal cancer diagnosisBreast cancer screeningLate-stage cancerEarly-stage cancerCancer incidence dataColorectal screeningResults databaseCancer screeningAdults 50Curable stageSubsequent diagnosisStage cancerDetects cancerNHS dataCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply